Clinical trial
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
NCT04931823
Study timeline
Study start (actual)2021-03-24Date precision: day
Registry last updated2026-04-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumorunresolved
Interventions
CPO-100DRUG
Sponsors & collaborators
Conjupro Biotherapeutics, Inc.lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04931823 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.